Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 122
Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
Research Type Human Reported as Case Report/Series/Restrospective Study Date July 05, 2018 Authors J.A. Miskoff, M. Chaudhri Institution Jersey Shore University Medical Center Disease Cancer (general), Lung Cancer
Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We presen...
Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness
Research Type Human Reported as Clinical Trial Date June 09, 2018 Authors K.L. Brewer, A. Mainhart, W.J. Meggs Institution East Carolina University Disease Gulf War Illness
BACKGROUND: 30% of Gulf War veterans developed Gulf War Illness (GWI) with chronic fatigue, pain, and neuropsychological disabilities. PURPOSE: To assess the efficacy of low-dose naltrexone to treat GWI. Methods: A double-blinded, placebo-controlled crossover trial of naltrexone 4.5 mg/day was conducted. The Clinical global impression scale (CGIS), visual analogue scales (VAS), SF-36 Health Survey, and the Connors Continuous Performance Test assessed treatment response. ...
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy
Research Type Human Reported as Review Date June 06, 2018 Authors Z. Li, Y. You, N. Griffin, J. Feng, F. Shan Institution Shengjing Hospital of China Medical University, Immune Therapeutics, Inc, China Medical University Disease AutoImmune (general), Cancer (general), Crohn's Disease, MS (Multiple Sclerosis)
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental diso...
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Research Type Lab (in-vitro) Date June 01, 2018 Authors Brianna Cote, Bethany Ross, Jeff Fortner, Deepa Rao Institution Oregon State University College of Pharmacy, Pacific University School of Pharmacy Disease Fibromyalgia
Fibromyalgia is a syndrome associated with chronic, widespread musculoskeletal pain, fatigue, depression, and cognitive dysfunction. With few U.S. Food and Drug Administration-approved treatment options, there is evidence that low-dose naltrexone, an opioid antagonist approved for opioid and alcohol dependence at high doses, may have efficacy in the treatment of fibromyalgia and chronic pain. At the doses required for fibromyalgia treatment, naltrexone needs to be compounded, and no data curre...
Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
Research Type Human Reported as Clinical Trial Date March 09, 2018 Authors Mitchell R. K. L. Lie, Janine van der Giessen, Gwenny M. Fuhler, Alison de Lima, Maikel P. Peppelenbosch, Cokkie van der Ent and C. Janneke van der Woude Institution Erasmus University Medical Center Rotterdam Disease Crohn's Disease, IBD, Ulcerative Colitis
BACKGROUND: Around 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or relapse over time. Novel treatments are called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible alternative treatment option for these patients. We investigated the potential of LDN to induce clinical response in therapy refractory IBD patients, and investigated its direct effects on epithelial barrier function. METHODS: Patients not in remission and not resp...
The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders.
Research Type Human Reported as Review Date January 27, 2018 Authors Denise K. Patten, Bob G. Schultz, Daniel J Berlau Institution Regis University School of Pharmacy Disease Crohn's Disease, Fibromyalgia, MS (Multiple Sclerosis), Pain (chronic)
Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off-label, complimentary, or alternative medicines to gain relief from symptoms. Low-dose naltrexone has been used off-label for treatment of pain and inflammation in multiple sclerosis, Crohn's disease, fibromyalgia, and other diseases. Naltrexone is a mu-opioid receptor antagonist indic...
The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 27, 2018 Authors Guttorm Raknes, Pia Simonsen, Lars Småbrekke Institution University Hospital of North Norway Disease Crohn's Disease, IBD, Ulcerative Colitis
BACKGROUND AND AIMS: Low dose naltrexone (LDN) is a controversial off-label treatment used by many Crohn’s disease (CD) and ulcerative colitis (UC) patients. A small number of preliminary studies indicate that LDN might be beneficial in CD, but evidence is too scarce to demonstrate efficacy. We wanted to examine whether initiation of LDN therapy by patients with inflammatory bowel disease (IBD) was followed by changes in dispensing of relevant medication. METHODS: We performed a quasi-experim...
Variable Response to Naltrexone in Patients With Hailey-Hailey Disease
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 17, 2018 Authors Severine Cao; Evelyn Lilly; Steven T. Chen Institution Harvard Medical School; Massachusetts General Hospital Disease Hailey-Hailey
Hailey-Hailey disease (HHD) is a genetic intraepidermal blistering disorder characterized by chronic macerated erosions in intertriginous areas. The recent report of 2 case series demonstrating the efficacy of low-dose naltrexone in the treatment of HHD represents exciting progress in the management of a disease with limited therapeutic options. Herein we present 3 additional cases of HHD demonstrating varying responses to naltrexone. ...
Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 11, 2018 Authors Leonard B Weinstock, Jill B Brook,Trisha L Myers, Brent Goodman Institution Washington University, Specialists in Gastroenterology, Mayo Clinic Arizona Disease MCAS (mast cell activation syndrome), POTS (postural orthostatic tachycardia)
A patient with severe postural orthostatic tachycardia syndrome (POTS ) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN), intravenous immunoglobulin (IVIg), and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCA...
Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis
Research Type Human Date January 01, 2018 Authors Ludwig MD, Zagon IS, McLaughlin PJ Institution Pennsylvania State University Disease MS (Multiple Sclerosis)
ABSTRACT: The endogenous neuropeptide opioid growth factor, chemically termed [Met5]-enkephalin, has growth inhibitory and immunomodulatory properties. Opioid growth factor is distributed widely throughout most tissues, is autocrine and paracrine produced, and interacts at the nuclear-associated receptor, OGFr. Serum levels of opioid growth factor are decreased in patients with multiple sclerosis and in animals with experimental autoimmune encephalomyelitis suggesting that the OGF-OGFr p...